Navigation Links
Life span of ovarian grafts longer than expected

Transplanting previously frozen ovarian tissue back into female cancer survivors can lead to long-term hormonal function and preservation of fertility, according to a new study by Samuel Kim from the University of Kansas Medical Center in the US. His work, which shows that hormonal function was restored in five women 12-20 weeks after transplantation, and in one case lasted for more than seven years, appears online in the Journal of Assisted Reproduction and Genetics, published by Springer.

Many female cancer patients want to remain fertile, and choose to freeze some of their ovarian tissue prior to cancer treatment. Following treatment, the frozen tissue is thawed and transplanted back into the survivor's body, in a different location - known as a 'heterotopic site'. However, the longevity of grafted ovarian tissue has been debated for many years, and it is still uncertain how long hormonal (endocrine) function of frozen-thawed ovarian tissue can be maintained.

Kim studied five cancer survivors who had undergone heterotopic ovarian transplantation between 2001-2011. Their frozen ovaries were rapidly thawed and transplanted into the abdominal region. Kim measured both the levels and function of the reproductive hormones in these women via monthly blood tests and ultrasounds after hormonal activity was confirmed. The women were monitored until cessation of hormonal function.

He found that hormonal function was restored in all five patients 12-20 weeks after transplantation. Long-term follow-up in four patients showed that these women needed a second transplantation within two years of the first. Interestingly, restoration of ovarian function after the second transplantation was faster and lasted longer, between nine months and seven years.

The longest duration of hormonal function was seen in a 28-year-old women who underwent ovarian transplantation in 2003 and 2004 after radiotherapy for cervical cancer. Even seven years after transplantation, the grafts were still producing hormones.

Kim concludes: "Re-establishment of long-term endocrine function after ovarian transplantation will benefit young cancer survivors with premature ovarian failure. To my knowledge, this is the longest duration of ovarian function reported in the literature after heterotopic transplantation of frozen-thawed human ovarian tissue."


Contact: Joan Robinson

Related biology news :

1. Researchers identify genes that may help in ovarian cancer diagnosis and prognosis
2. Longer sleep times may counteract genetic factors related to weight gain
3. Pain relief with PAP injections may last 100 times longer than a traditional acupuncture treatment
4. Global Surgical Devices Market Growth Driven by Improving Standards of Living and Longer Life Expectancies, Research Shows
5. Study suggests why some animals live longer
6. The millennium-old olive trees of the Iberian Peninsula are younger than expected
7. Unexpected discovery reveals a new mechanism for how the cerebellum extracts signal from noise
8. Unexpected crustacean diversity discovered in northern freshwater ecosystems
Post Your Comments:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... BC (PRWEB) , ... November 24, 2015 , ... ... our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast ... Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that ...
(Date:11/24/2015)... HemoShear Therapeutics, LLC, a privately held ... disorders, announced today the appointment of H. ... (BOD). Mr. Watkins is the former president and ... and also served as the chairman of the ... Chairman and CEO of HemoShear Therapeutics. "The combination ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
Breaking Biology Technology: